RJA
FOLD

Raymond James & Associates’s Amicus Therapeutics FOLD Stock Holding History

Raymond James & Associates’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-11,000
Closed -$30K – 3615
2020
Q2 		$30K Hold
11,000
– – ﹤0.01% 3421
2020
Q1 		$7K Sell
11,000
-5,000
-31% -$47.5K ﹤0.01% 3459
2019
Q4 		$2K Buy
+16,000
New +$146K ﹤0.01% 3654

Other funds holding FOLD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Raymond James & Associates's FOLD Position: Q4 2023 in Review

Raymond James & Associates sold out of Amicus Therapeutics (FOLD) in Q4 2023, closing a stake of 10,735 shares — an estimated $131K sold.

Raymond James & Associates first reported a position in FOLD in Q4 2015 and held it in 23 quarters. The position peaked at $2.87M in Q3 2017. 228 funds tracked by Wall St. Rank hold FOLD as of Q4 2023.

  • Raymond James & Associates reported no remaining Amicus Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Raymond James & Associates sold 10,735 Amicus Therapeutics shares in Q4 2023, an estimated $131K.
  • Raymond James & Associates first reported a position in Amicus Therapeutics in Q4 2015 and held it in 23 quarters.
  • Raymond James & Associates's Amicus Therapeutics position peaked at $2.87M in Q3 2017.
  • 228 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2023.

Based on Raymond James & Associates's 13F filing for Q4 2023, filed 16 Jan 2024.